NEW YORK (GenomeWeb News) — Amaxa said today that it will coordinate an eight-member European alliance to develop devices for ultra-high-throughput transfection of primary cells.
The European Commission awarded the partnership more than €2.75 million ($3.7 million) in funding. The group will use Amaxa’s Nucleofector technology, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.